Pharmacology of Terbinafine

Introduction/Overview

Terbinafine represents a cornerstone agent in the modern pharmacotherapy of superficial fungal infections. As a synthetic allylamine antifungal, it has established a primary role in the management of dermatophytoses, particularly onychomycosis, where its fungicidal activity and favorable pharmacokinetic profile offer distinct therapeutic advantages. The clinical importance of terbinafine is underscored by the high global prevalence of cutaneous fungal infections and the significant morbidity, recurrence, and treatment challenges associated with these conditions. Its development marked a significant advancement over earlier antifungal classes, providing a more targeted and potent therapeutic option.

The following learning objectives are intended to guide the study of this chapter:

• Describe the chemical classification of terbinafine and its relationship to pharmacologic activity.
• Explain the molecular mechanism of action, detailing the inhibition of ergosterol biosynthesis and its fungicidal consequences.
• Analyze the pharmacokinetic properties of terbinafine, including absorption, distribution, metabolism, and excretion, and their implications for dosing regimens.
• Identify the approved clinical indications for terbinafine and evaluate the evidence supporting its use in specific fungal infections.
• Recognize the spectrum of adverse effects, significant drug interactions, and special population considerations essential for safe clinical prescribing.

Classification

Terbinafine is definitively classified within the allylamine class of antifungal agents. This classification is based on its chemical structure, which features an allylamine side chain essential for its mechanism of action. It is distinct from other major antifungal classes such as azoles (which inhibit lanosterol 14α-demethylase), polyenes (which bind to ergosterol in the fungal membrane), and echinocandins (which inhibit glucan synthesis).

Chemical Classification

Chemically, terbinafine is designated as (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. It is a derivative of naphthalene, synthesized as a lipophilic molecule. This lipophilicity is a critical determinant of its pharmacokinetic behavior, facilitating extensive tissue distribution and accumulation in structures like the stratum corneum, hair, and nails. The allylamine functional group is directly responsible for the drug’s interaction with its target enzyme, squalene epoxidase.

Mechanism of Action

The pharmacodynamic profile of terbinafine is characterized by potent, specific, and fungicidal activity against dermatophytes and certain other fungi. Its mechanism is fundamentally rooted in the selective inhibition of a key enzyme in the fungal sterol biosynthesis pathway.

Molecular and Cellular Mechanisms

Terbinafine exerts its primary antifungal effect through non-competitive, specific inhibition of the enzyme squalene epoxidase. This enzyme is a microsomal flavin adenine dinucleotide (FAD)-dependent monooxygenase that catalyzes the conversion of squalene to 2,3-oxidosqualene in the early stages of ergosterol biosynthesis. Ergosterol is the principal sterol component of the fungal cell membrane, analogous to cholesterol in mammalian cells, and is essential for maintaining membrane integrity, fluidity, and the function of membrane-bound enzymes.

Inhibition of squalene epoxidase has two principal cytotoxic effects on fungal cells. First, the blockade leads to a depletion of ergosterol within the fungal membrane. This depletion compromises membrane structure and function, impairing cellular processes such as nutrient transport and enzyme activity. Second, and perhaps more critically for the fungicidal action, the inhibition causes intracellular accumulation of squalene. Squalene is a highly lipophilic and toxic metabolite when present in high concentrations. Its accumulation within the fungal cell leads to membrane disruption, increased membrane permeability, and eventual cell lysis and death. This dual action—ergosterol depletion coupled with squalene accumulation—is responsible for the fungicidal, rather than fungistatic, activity of terbinafine against susceptible organisms.

Spectrum of Activity

The activity of terbinafine is most potent against dermatophytes, including Trichophyton species (e.g., T. rubrum, T. mentagrophytes), Microsporum species, and Epidermophyton floccosum. It also demonstrates activity against many dimorphic fungi, such as Histoplasma capsulatum and Blastomyces dermatitidis, and has variable activity against some molds and Candida species, though it is generally not considered a first-line agent for candidiasis. Its action against fungi is highly selective due to the much higher affinity for fungal squalene epoxidase compared to the analogous enzyme in human cholesterol biosynthesis (squalene monooxygenase), resulting in a favorable therapeutic index.

Pharmacokinetics

The pharmacokinetic properties of terbinafine are characterized by extensive tissue distribution, significant first-pass metabolism, and a prolonged terminal half-life that supports once-daily oral dosing and contributes to its efficacy in nail infections.

Absorption

Following oral administration, terbinafine is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations (C_max) typically achieved within 2 hours. The absolute bioavailability is approximately 40-50%, due to significant first-pass metabolism. Absorption is enhanced by a high-fat meal, which can increase bioavailability by up to 100%. Therefore, administration with food is generally recommended to ensure consistent and adequate systemic exposure. Topical formulations are minimally absorbed through intact skin, resulting in negligible systemic concentrations.

Distribution

Terbinafine is highly lipophilic and exhibits a large volume of distribution (>2000 L), indicating extensive penetration into tissues. It demonstrates high affinity for keratinous tissues, including skin, hair, and nails. Concentrations in the stratum corneum, sebum, and hair far exceed simultaneous plasma levels. Notably, the drug persists in the nail plate for weeks to months after discontinuation of therapy, which is a key factor in the success of pulse or short-course dosing regimens for onychomycosis. Plasma protein binding exceeds 99%, primarily to albumin and lipoproteins.

Metabolism

Terbinafine undergoes extensive hepatic metabolism via multiple cytochrome P450 isoenzymes, including CYP2C9, CYP1A2, CYP3A4, and CYP2C8. It does not inhibit or induce these enzymes to a clinically significant degree. The primary metabolic pathways involve N-demethylation, alkyl side-chain oxidation, and deamination, resulting in at least 15 metabolites. None of these metabolites possess significant antifungal activity. The extensive metabolism contributes to the numerous potential drug interactions.

Excretion

Elimination occurs primarily via the urine, with over 70% of an administered dose excreted as metabolites. Less than 0.1% is excreted unchanged in the urine. The remainder is eliminated in the feces. The elimination half-life (t_1/2) is biphasic. The initial half-life is about 12-24 hours, while the terminal half-life from deep tissue compartments is prolonged, ranging from 200 to 400 hours. This prolonged terminal phase reflects slow release from adipose tissue and skin. Systemic clearance is estimated at approximately 75 L/h.

Pharmacokinetic Parameters and Dosing

The standard adult oral dose is 250 mg once daily. For onychomycosis of the fingernails, a 6-week course is typical, while toenail infections usually require a 12-week course. The relationship between dose and systemic exposure (AUC) is linear within the therapeutic range. The pharmacokinetics support once-daily dosing due to the drug’s long half-life and post-antifungal effect, where antifungal activity persists after serum levels have declined.

Therapeutic Uses/Clinical Applications

Terbinafine is indicated for the treatment of specific fungal infections where its tissue-penetrating and fungicidal properties provide a therapeutic advantage. Its use is supported by extensive clinical trial data demonstrating high mycological and clinical cure rates.

Approved Indications

The primary approved indications for oral terbinafine are the treatment of onychomycosis of the toenail or fingernail due to dermatophytes and tinea capitis. For topical formulations, indications include tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), and cutaneous candidiasis (moniliasis).

• Onychomycosis: This represents the most common and well-established indication. Terbinafine is considered a first-line oral therapy due to superior mycological cure rates and shorter treatment durations compared to older agents like griseofulvin. Cure rates for toenail onychomycosis typically range from 70% to 80%.
• Tinea Capitis: It is effective against dermatophyte infections of the scalp, often caused by Microsporum and Trichophyton species. Treatment duration is usually 4 to 6 weeks.
• Dermatophyte Infections (Topical): Cream, gel, or spray formulations are applied once or twice daily for 1 to 4 weeks, depending on the infection site and severity, for various tinea infections.

Off-Label Uses

Several off-label applications are supported by clinical evidence, though they may not be formally approved in all jurisdictions. These include the treatment of extensive or recalcitrant tinea corporis/cruris not responsive to topical therapy, cutaneous infections due to non-dermatophyte molds (e.g., Scytalidium), and as an alternative or adjunctive agent in the management of certain systemic mycoses like chromoblastomycosis or sporotrichosis. Its use in pityriasis versicolor, caused by Malassezia species, is limited as this yeast is not typically susceptible to terbinafine.

Adverse Effects

Terbinafine is generally well-tolerated, particularly in its topical form. Oral administration is associated with a predictable profile of adverse reactions, ranging from common and mild to rare but serious events.

Common Side Effects

The most frequently reported adverse effects involve the gastrointestinal tract and are often self-limiting. These include dyspepsia, abdominal pain, nausea, diarrhea, and flatulence. Other common effects involve disturbances in taste (dysgeusia) or smell, which are usually reversible upon discontinuation but may persist for several weeks. Headache, rash, and pruritus are also reported with some frequency. Topical application may cause local irritation, burning, itching, or dryness at the site of application.

Serious and Rare Adverse Reactions

Although uncommon, several serious adverse reactions necessitate careful patient monitoring and prompt discontinuation of therapy.

• Hepatotoxicity: Asymptomatic elevation of liver enzymes (transaminases) occurs in approximately 3-4% of patients. In rare instances (estimated incidence of 1 in 45,000 to 1 in 120,000 prescriptions), terbinafine can cause clinically symptomatic hepatitis, including cholestatic hepatitis, which can be severe and lead to acute liver failure requiring transplantation. Baseline and periodic monitoring of liver function tests is recommended during prolonged courses (>6 weeks).
• Hematologic Effects: Severe neutropenia, agranulocytosis, thrombocytopenia, and pancytopenia have been reported rarely. Patients should be advised to report signs of infection or unusual bleeding/bruising.
• Serious Skin Reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis (AGEP) have been documented. The drug should be discontinued at the first appearance of a severe rash.
• Psychiatric and Neurological Effects: Depression, anxiety, and, in very rare cases, taste and smell disturbances progressing to loss (ageusia, anosmia) have been reported. Sensory disturbances or paresthesias may also occur.
• Ocular Effects: Cases of visual field defects, optic neuritis, and permanent vision loss have been described, though a direct causal relationship is difficult to establish.

Black Box Warnings

Terbinafine does not carry a formal black box warning from regulatory agencies like the U.S. Food and Drug Administration. However, prescribing information contains strong warnings regarding the risk of hepatotoxicity and serious skin reactions, and it is contraindicated in patients with chronic or active liver disease.

Drug Interactions

As a substrate of multiple CYP450 enzymes and due to its pharmacokinetic properties, terbinafine participates in several clinically significant drug interactions. It is a moderate inhibitor of the CYP2D6 isoenzyme, which is the basis for its most notable interactions.

Major Drug-Drug Interactions

• CYP2D6 Substrates: Terbinafine can increase plasma concentrations of drugs metabolized primarily by CYP2D6. This includes many tricyclic antidepressants (e.g., amitriptyline, nortriptyline), selective serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine), beta-blockers (e.g., metoprolol, propranolol), and some antipsychotics (e.g., haloperidol, risperidone). Dose adjustment and monitoring for toxicity of these co-administered drugs may be necessary.
• CYP450 Inducers and Inhibitors: Drugs that induce CYP450 enzymes (e.g., rifampin, phenytoin, carbamazepine) can increase the metabolism of terbinafine, potentially reducing its plasma concentrations and efficacy. Conversely, potent CYP450 inhibitors (e.g., cimetidine) may increase terbinafine levels, though this is less commonly a clinical concern.
• Warfarin: Although terbinafine does not significantly affect CYP2C9, the primary metabolizer of S-warfarin, isolated cases of increased International Normalized Ratio (INR) have been reported. Monitoring of INR is advisable when initiating or discontinuing terbinafine in patients on warfarin.
• Caffeine: Terbinafine may reduce the clearance of caffeine, potentially prolonging its stimulant effects.

Contraindications

Terbinafine is contraindicated in individuals with known hypersensitivity to terbinafine or any component of its formulation. Its use is also contraindicated in patients with chronic or active liver disease, given the risk of hepatotoxicity. Caution is warranted, and often avoidance is recommended, in patients with a history of blood dyscrasias or severe cutaneous adverse reactions to other drugs.

Special Considerations

The use of terbinafine requires careful evaluation in specific patient populations due to altered pharmacokinetics, increased risk of adverse events, or potential for fetal harm.

Pregnancy and Lactation

Terbinafine is classified as Pregnancy Category B in older classification systems, indicating that animal reproduction studies have not demonstrated a fetal risk, but there are no adequate and well-controlled studies in pregnant women. Given that the treatment of onychomycosis and other superficial fungal infections is rarely urgent, the use of oral terbinafine during pregnancy is generally not recommended. Topical application is considered to have minimal systemic absorption and may be used if clearly needed, though the affected area should be as small as possible. Terbinafine is excreted in human breast milk, and because of the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric and Geriatric Considerations

Oral terbinafine is approved for use in children for tinea capitis. Dosing is based on body weight. Pharmacokinetic studies suggest that children may have a lower systemic exposure (AUC) for a given mg/kg dose compared to adults, but clinical efficacy remains high. In elderly patients, no specific dose adjustment is routinely recommended based on age alone. However, age-related declines in renal or hepatic function, as well as a higher likelihood of polypharmacy, necessitate increased vigilance for adverse effects and drug interactions.

Renal and Hepatic Impairment

In patients with renal impairment (creatinine clearance ≤ 50 mL/min), the clearance of terbinafine is reduced by approximately 50%. While no specific dose adjustment is provided in labeling for mild to moderate impairment, a reduction in dose (e.g., 250 mg every other day) may be considered in severe renal impairment. The drug is contraindicated in hepatic impairment. As previously emphasized, baseline liver function tests are recommended before initiating therapy in any patient, and therapy should be discontinued if hepatic enzyme elevations exceed twice the upper limit of normal or if symptomatic hepatitis develops.

Summary/Key Points

• Terbinafine is a synthetic, fungicidal allylamine antifungal that inhibits squalene epoxidase, leading to ergosterol depletion and toxic squalene accumulation within fungal cells.
• Its pharmacokinetics are defined by high lipophilicity, extensive tissue distribution (particularly to skin, hair, and nails), significant first-pass metabolism by multiple CYP450 enzymes, and a prolonged terminal half-life supporting once-daily dosing.
• The primary clinical indications are onychomycosis and tinea capitis for the oral formulation, and various cutaneous dermatophyte infections for topical preparations.
• Common adverse effects include gastrointestinal disturbances and taste disorders. Serious but rare risks include hepatotoxicity, severe skin reactions, hematologic dyscrasias, and visual disturbances.
• Terbinafine is a moderate inhibitor of CYP2D6, leading to clinically significant interactions with drugs metabolized by this pathway, such as certain antidepressants and beta-blockers.
• Use is contraindicated in patients with liver disease. Special caution is required in patients with renal impairment, and its use is generally avoided during pregnancy and lactation.

Clinical Pearls

• For oral therapy, administration with a high-fat meal significantly enhances bioavailability and should be standard practice.
• The “post-treatment” therapeutic effect in nails, due to prolonged tissue persistence, means clinical improvement often continues for months after stopping the medication.
• Baseline liver function tests are recommended before starting oral therapy, and patients should be counseled to discontinue the drug and seek medical attention for symptoms of hepatitis (e.g., fatigue, anorexia, nausea, jaundice, dark urine) or severe skin rash.
• When prescribing for a patient on a CYP2D6 substrate, consider the potential for increased substrate levels and monitor for signs of toxicity; a dose reduction of the interacting drug may be required.
• Topical terbinafine is a highly effective and safe first-line treatment for uncomplicated tinea corporis, cruris, and pedis, with minimal systemic exposure.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.